Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
In September 2023, the FDA added injectable GHK-Cu to a list of compounded substances considered high-risk due to limited safety data
The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its [PMID: 38675421] Laboratory literature summary: The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity
For some users, subtle changes may even appear within 1-2 weeks of routine application
~15 to 20 mmHg in some studies Cardioprotection data / Reduced infarct size and improved ejection fraction in rodent ischemia-reperfusion models Human RCT data / Zero completed cardiovascular-specific RCTs as of January 2025 Typical compounded dose range / 250 to 500 mcg/day subcutaneous or oral
